Subscribe To
Eur/gbp price analysis: remains subdued and oscillates above 0.8600 amid risk-off impulse
The EUR/GBP extended its losses to five straight trading days and hovers at around the September 28 swing low of 0.8629, amidst a risk-off impulse cou...
October 9, 2023, 11:29 pm
S&p 500 hits two-week high of $4,340 as equities shrug off gaza escalation fears
The Standard & Poor’s (S&P) 500 equity index is trading near $4,330, a two-week high for the index after markets recovered from an early Monday spat...
October 9, 2023, 10:00 pm
Middle east conflict sparks concerns over crude oil prices
Middle East Conflict Sparks Concerns Over Crude Oil Prices Crude oil prices experienced a sharp spike in the wake of a major offensive by Hamas on Isr...
October 9, 2023, 3:13 pm
Oil prices rally on fear of middle east supply disruptions
The Israel and Palestinian territories are not oil producers. But the Middle Eastern region accounts for almost a third of global supply. A wave of at...
October 9, 2023, 6:14 am
Nuvalent (nuvl) soars 36% on upbeat initial nsclc study data
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion ...
October 5, 2023, 12:02 pm
Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replica...
October 5, 2023, 12:00 pm
Black diamond therapeutics to present preclinical and clinical data at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology ...
October 4, 2023, 12:14 pm
Don't miss the boom: 3 machine learning stocks set to explode higher
The United States has been facing a confluence of threats that risk more turbulence. Currently, there are several potential challenges to contend with...
September 28, 2023, 6:42 am
Gm: we do have contingency plans, and will do what's best for the company, and customers:
escalation of a strike by UAW's top leadership is unnecessaryWe have now presented 5 separate economic ...
September 22, 2023, 5:27 pm
Realty income: it is not a fixed-income investment
Realty Income Corporation's year-to-date slump is a reminder that the REIT is not a risk-off investment. Although Realty Income completed high-yieldin...
September 20, 2023, 10:49 am
Harpoon therapeutics abstract for hpn217 accepted for poster presentation at the 20th international myeloma society annual meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company d...
September 6, 2023, 11:30 am
Chevron faces two-week total strike at australia lng projects
Workers at Chevron's Gorgon and Wheatstone liquefied natural gas (LNG) projects in Australia plan a total strike for two weeks from Sept. 14, a union ...
September 4, 2023, 9:03 pm
Glencore slips as investors seek damages over prospectus claims
Shares in Glencore PLC (LSE:GLEN) are firmly in the red after dozens of the world's biggest asset managers accused it of lying in past share prospectu...
August 31, 2023, 7:12 am
Us restricts exports of nvidia ai chips to middle east
Restrictions apply to A100 and H100 chips, in escalation of US efforts to restrict China's access to pr...
August 31, 2023, 5:47 am
Here's why one should sell canadian pacific kansas city (cp)
An escalation in operating expenses hurt Canadian Pacific Kansas City (CP)....
August 22, 2023, 8:17 pm
Perspective therapeutics announces first patient dosed in phase 1/2a dose escalation trial of vmt01 of its targeted alpha-particle therapy (tat), for treatment of mc1r-positive metastatic melanoma
First patient with MC1R–positive metastatic melanoma treated with 212Pb–VMT01 Preliminary data readout from dose ...
August 11, 2023, 12:05 pm
Perspective therapeutics reports second quarter fiscal 2023 results and recent business highlights
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected ...
August 11, 2023, 12:00 pm
Werewolf therapeutics reports second quarter 2023 financial results and provides business update
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human cl...
August 10, 2023, 11:10 am
Caribou biosciences: positive cb-010 data leads to first half 2024 catalyst
Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/ref...
July 17, 2023, 5:11 am
Biomea fusion: potential cure for diabetes, initiating with a buy
Biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with its lead asset BMF-219 showing promising initial...
July 16, 2023, 1:39 am